EP2430427A1 - Verfahren und vorrichtung zur erkennung von tumorbehaftetem lebendem zellgewebe - Google Patents
Verfahren und vorrichtung zur erkennung von tumorbehaftetem lebendem zellgewebeInfo
- Publication number
- EP2430427A1 EP2430427A1 EP10730694A EP10730694A EP2430427A1 EP 2430427 A1 EP2430427 A1 EP 2430427A1 EP 10730694 A EP10730694 A EP 10730694A EP 10730694 A EP10730694 A EP 10730694A EP 2430427 A1 EP2430427 A1 EP 2430427A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- cell tissue
- tumor
- intensity
- electromagnetic radiation
- fractal dimension
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/0059—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/0059—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
- A61B5/0071—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence by measuring fluorescence emission
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/6408—Fluorescence; Phosphorescence with measurement of decay time, time resolved fluorescence
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/6486—Measuring fluorescence of biological material, e.g. DNA, RNA, cells
Definitions
- the invention relates to a method and a device for detecting tumor-infected living cell tissue. It further relates to a method and an apparatus for detecting tumor-infected cell tissue on living sampled cell tissue samples.
- tumor-affected cell tissue In the various types of carcinoma occurring, it is common practice to surgically remove tumor-affected cell tissue. It is necessary to remove the affected cell tissue completely, so that the progression and spread of the disease can be avoided. Especially in the case of prostate cell tissue, it is desirable to obtain the highest possible proportion of unaffected cell tissue in order to further ensure necessary functions (continence, potency). It is therefore necessary to localize tumor-associated cell tissue in order to treat affected cell subsequently be able to remove tissue in a more targeted manner.
- tumor-tolerated cell tissue is sensitized to light with suitable chemical substances and, upon irradiation with light, fluorescence is excited on cells prepared in this way. In this case, the light to excite a different color than the fluorescent light.
- the substances used are highly phototoxic and can cause necrosis on appropriately treated tissue. However, this can also be exploited for a therapy against carcinoma tumors. However, knowledge of the position and spread of tumor-associated cell tissue is required.
- 5-ALA-induced detection in which 5-aminolevulinic acid is injected, or processes which are known commercially as Hexvix and TOOKAD and in which other photoactive substances are used be used.
- DE 689 25 586 T2 discloses a method for laser-induced fluorescence of tissue. In which a detection of certain cell tissue types by a fluorescence excitation and the detection of certain characteristic wavelengths in the detected wavelength spectrum of the fluorescent light to the respective cell tissue type is to be concluded.
- this object is achieved by a method having the features of claim 1 and of claim 2, respectively.
- the method can be carried out with a device according to claim 15.
- Advantageous embodiments and further developments of the invention can be achieved with features described in the subordinate claims.
- the inventive method according to claim 1 is carried out on living cell tissue.
- the method can also be carried out on a removed living cell tissue sample (in vitro).
- electromagnetic radiation is locally defined with a radiation source emitted to the cell tissue sample and after switching off the radiation source at time to the cell tissue, the decay behavior of the stimulated by the electromagnetic radiation autofluorescence intensity of the cell tissue with time and spectrally detected.
- the detection of the intrinsic fluorescence intensity takes place with one or more known sampling rate (s) and is carried out for at least one wavelength.
- the sampling rate is kept constant during the detection.
- R (t-to) ⁇ I (t) ⁇ I (t o )> t / ⁇ I 2 > t and
- I (t ⁇ ⁇ ) is the intensity of the excited fluorescent light after infinitely long relaxation, which is very small.
- the relaxation function R (t) results from the correlation function of the fluorescence fluctuations, where ⁇ > t represents the time average.
- the exponent H or the fractal dimension of the stochastic intensity fluctuations D F which can be calculated from this is a characteristic variable for the evaluation.
- D F 2 - H and can be used to distinguish between healthy and tumor-infected cell tissue.
- the exponent H can be determined by linear regression.
- the value D F can be used for a classification with regard to a tumor adhesion of the respective irradiated cell tissue.
- a comparison with a tumor-specific threshold can be performed.
- it may also be an indication of a probability of a tumor in the classification.
- the fractal dimension D F is calculated for the respective irradiated cell tissue and the value of the determined fractal dimension D F can then be compared with a tumor-specific threshold value.
- the threshold value is exceeded, the irradiated cell tissue of the cell tissue sample is classified as having a tumor. If it falls below this threshold, the cell tissue is healthy.
- the threshold is a number between 1 and 2.
- irradiation, detection and calculation of the fractal dimension D F can be performed on the examined cell tissue or on the respective cell tissue sample at several positions, in order to localize healthy cell tissue and possibly tumor-bearing cell tissue.
- Electromagnetic radiation in the wavelength range between 200 nm and 650 nm is particularly suitable here.
- Laser sources can be used as the radiation source.
- For the excitation of the self-fluorescence has become electromagnetic radiation having a wavelength of 337 nm proved to be favorable.
- only a selected wavelength can be detected from the spectrum of the autofluorescence of the cell tissue to be examined and then taken into account.
- the difference between the distances of the wavelengths considered from this wavelength interval should be the same in each case.
- the detection can be performed within a wavelength interval of 421 nm ⁇ 15 nm.
- the detection can be carried out with a spectrometer and detected at a sampling rate ⁇ 10000 ps, preferably ⁇ 100 ps, particularly preferably at about 50 ps.
- the electromagnetic radiation for the excitation of the intrinsic fluorescence can be directed onto the cell tissue via at least one optical fiber and, after the radiation source has been switched off, the intrinsic fluorescence light can be directed onto the detector via the same optical fiber (s).
- a beam splitter can be used with which the electromagnetic radiation emitted by the cell tissue sample and used for the detection can be directed onto the detector. It is favorable to carry out the irradiation and detection within a non-transparent chamber.
- Cell tissue samples to be detected should be cooled before and during detection while maintaining a constant temperature. It should preferably be maintained at a temperature of 15 0 C. A temperature control is favorable in order to be able to comply with comparable conditions.
- Cell tissue samples can be cooled on a sample rack or in the chamber where the examination is performed. Suitable coolants or elements suitable for cooling may be arranged thereon or therein.
- the tests on cell tissue or a cell tissue sample can be carried out successively or simultaneously at several positions.
- electromagnetic radiation can be directed, for example via a plurality of appropriately arranged optical fibers for excitation of autofluorescence on cell tissue or the cell tissue sample to different locations and then after switching off the radiation source intensity I (t) of the resulting due to the intrinsic fluorescence of the cell tissue from there electromagnetic Radiation via optical fibers are led to a detector.
- an examination can be carried out promptly and, if necessary, directly in an operating room.
- tumor-bearing cell tissue of healthy cell tissue with very high
- the invention provides a good basis for deciding where and how much cell tissue is to be surgically removed.
- An apparatus for carrying out the method according to the invention is designed such that living cell tissue or else a removed live cell tissue sample is subjected to locally defined exposure to electromagnetic radiation emitted by a radiation source and a detector for the time-resolved and spectrally resolved detection of the autofluorescence intensity of the respectively pre-irradiated cell tissue, is connected to an electronic evaluation unit, with which the difference autocorrelation intensity can be determined from the determined intensity measured values.
- Function C (t) can be determined.
- the fractal dimension D F can be calculated and this value of the fractal dimension D F can be compared with a tumor-specific threshold value.
- the device can be designed such that a part in which at least one detector for time-resolved and spectrally resolved detection of the intrinsic fluorescence intensity and in the cell tissue can be examined, is to be examined in an organ on the cell tissue To carry out an investigation directly on the living organism.
- a time-consuming preparation of the cell tissue to be examined, as required in a frozen section, is eliminated.
- the burden on patients during surgery can be reduced because the examination result is available in a much shorter time. It can be easily distinguished between malignant and benign cell tissues.
- FIG. 1 shows a diagram of the time-resolved intensity-decay behavior with a constant wavelength of 421 nm
- FIG. 2 shows a diagram of the time-resolved intensity-decay behavior that has been created with the mean value of several wavelengths within a wavelength interval around the wavelength of 421 nm and FIG
- Figure 3 shows the course of the difference autocorrelation function over time when the intensity fades.
- prostate cell tissue was taken from patients in the form of punches.
- the cell tissue samples thus obtained were placed in a groove representing an uptake of the cell tissue samples and electromagnetic radiation directed via an optical fiber to certain predetermined positions of the cell tissue samples.
- the radiation source used was a nitrogen laser.
- the electromagnetic radiation used for self-fluorescence excitation of the cell tissue had a wavelength of 337 nm.
- the collected cell samples were cooled to a temperature of 15 0 C and held at least until after completion of the study at this temperature.
- the electromagnetic radiation emitted by the cell tissue as a result of the autofluorescence was directed onto a spectrometer via the same optical fiber, with which a detection in the wavelength interval of about 300 nra to about 600 nm was possible.
- a characteristic wavelength of 421 nm was selected at which increased intensities of intrinsic fluorescence occurred.
- the value of the fractal dimension D F can be determined with the difference autocorrelation function ascertained and the rise of a straight line with (t-to) 2H and knowledge of the exponent H.
- the determined value D F can be compared with a tumor-specific threshold value for the respectively examined position of the respective cell tissue sample.
- this threshold was between 1.31 and 1.32.
- Differentiated cellular tissue conditions such as benign prostatic hyperlapse (BPN) or prostatic intra-epithelial neolapse (PIN), as a precursor to prostate cancer, can also be distinguished.
- BPN benign prostatic hyperlapse
- PIN prostatic intra-epithelial neolapse
- the cell tissue examined at the respective cell tissue sample is free from tumor cells, healthy cell tissue.
- the invention can also be carried out on at least two detectable with the spectrometer wavelengths, which have a greater distance from each other.
- the temporal intensity decay behavior can be carried out, for example, at the wavelengths 370 nm and 430 nm, if appropriate also with a described averaging.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Biophysics (AREA)
- Medical Informatics (AREA)
- Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10730694A EP2430427A1 (de) | 2009-05-15 | 2010-05-12 | Verfahren und vorrichtung zur erkennung von tumorbehaftetem lebendem zellgewebe |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09006583A EP2251675A1 (de) | 2009-05-15 | 2009-05-15 | Verfahren zur Erkennung von Tumorbehaftetem Zellgewebe |
DE102009031775 | 2009-07-01 | ||
EP10730694A EP2430427A1 (de) | 2009-05-15 | 2010-05-12 | Verfahren und vorrichtung zur erkennung von tumorbehaftetem lebendem zellgewebe |
PCT/DE2010/000559 WO2010130254A1 (de) | 2009-05-15 | 2010-05-12 | Verfahren und vorrichtung zur erkennung von tumorbehaftetem lebendem zellgewebe |
Publications (1)
Publication Number | Publication Date |
---|---|
EP2430427A1 true EP2430427A1 (de) | 2012-03-21 |
Family
ID=42671755
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP10730694A Withdrawn EP2430427A1 (de) | 2009-05-15 | 2010-05-12 | Verfahren und vorrichtung zur erkennung von tumorbehaftetem lebendem zellgewebe |
Country Status (4)
Country | Link |
---|---|
US (1) | US8981317B2 (de) |
EP (1) | EP2430427A1 (de) |
KR (1) | KR101746010B1 (de) |
WO (1) | WO2010130254A1 (de) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102010024732A1 (de) | 2010-06-23 | 2011-12-29 | Siemens Aktiengesellschaft | Verfahren und Vorrichtung zur Erkennung von tumorbehaftetem Gewebe im Gastrointestinaltrakt mit Hilfe einer Endokapsel |
EP2665404A1 (de) | 2011-01-20 | 2013-11-27 | Tel HaShomer Medical Research Infrastructure and Services Ltd. | Verfahren und vorrichtungen zur bereitstellung von nützlichen informationen für die diagnose von anomalien im magen-darm-trakt |
GB2487940B (en) | 2011-02-09 | 2014-12-17 | Tel Hashomer Medical Res Infrastructure & Services Ltd | Methods and devices suitable for imaging blood-containing tissue |
EP2699159B1 (de) * | 2011-04-20 | 2016-04-06 | IM Co., Ltd. | Vorrichtung zur prostatakrebsdiagnose mit fraktalem dimensionswert |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE133545T1 (de) | 1988-12-21 | 1996-02-15 | Massachusetts Inst Technology | Verfahren für laserinduzierte fluoreszenz von gewebe |
JP2005504561A (ja) | 2001-03-01 | 2005-02-17 | トラスティーズ・オブ・ダートマウス・カレッジ | 蛍光寿命分光計(fls)および病変組織の検出方法 |
US20100292543A1 (en) | 2007-10-30 | 2010-11-18 | Tufts University | Analysis of Endogenous Fluorescence Images to Extract Morphological/Organization Information About Living Samples |
-
2010
- 2010-05-12 EP EP10730694A patent/EP2430427A1/de not_active Withdrawn
- 2010-05-12 WO PCT/DE2010/000559 patent/WO2010130254A1/de active Application Filing
- 2010-05-12 US US13/320,610 patent/US8981317B2/en active Active
- 2010-05-12 KR KR1020117030090A patent/KR101746010B1/ko active IP Right Grant
Non-Patent Citations (6)
Title |
---|
ANONYMOUS: "Web-OPAC V3.0.0.8477", 1 January 2013 (2013-01-01), XP055336933, Retrieved from the Internet <URL:http://bond.azw.ac.at/webopac/index.asp?detmediennr=2> [retrieved on 20170119] * |
GERICH C E ET AL: "Detection of cancer cells in prostate tissue with time-resolved fluorescence spectroscopy", OPTICAL INTERACTIONS WITH TISSUE AND CELLS XXII, SPIE, 1000 20TH ST. BELLINGHAM WA 98225-6705 USA, vol. 7897, no. 1, 10 February 2011 (2011-02-10), pages 1 - 12, XP060007307, DOI: 10.1117/12.876094 * |
GERICH CE, OPITZ J, SCHREIBER J: "Machbarkeits-Studie Zeitaufgelöste Fluoreszenz zur Krebsdiagnose. Fraunhofer Institut für zerstörungsfreie Prüfverfahren", 30 September 2008, FRAUNHOFER INSTITUT FÜR ZERSTÖRUNGSFREIE PRÜFVERFAHREN, Dresden * |
GERICH CE: "Diplom-Arbeit: Untersuchung zum nicht-exponentiellen Abklingverhalten von Laser induzierter Auto-Fluoreszenz zur Diagnose von Prostata-Carcinom", 2008, EDUARD WALLNÖFER ZENTRUM 1: UMIT PRIVATE UNIVERSITÄT FÜR GESUNDHEITSWISSENSCHAFTEN * |
JAN KLATT ET AL: "Fractal dimension of time-resolved autofluorescence discriminates tumour from healthy tissues in the oral cavity", JOURNAL OF CRANIO-MAXILLO-FACIAL SURGERY, vol. 42, no. 6, 1 September 2014 (2014-09-01), GB, pages 852 - 854, XP055329228, ISSN: 1010-5182, DOI: 10.1016/j.jcms.2013.12.004 * |
See also references of WO2010130254A1 * |
Also Published As
Publication number | Publication date |
---|---|
US8981317B2 (en) | 2015-03-17 |
KR20120036855A (ko) | 2012-04-18 |
US20120252057A1 (en) | 2012-10-04 |
WO2010130254A1 (de) | 2010-11-18 |
KR101746010B1 (ko) | 2017-06-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69532108T2 (de) | Krebsdiagnose durch laserinduzierte differential-normierte fluoreszenz | |
EP2336751B1 (de) | Verfahren zur Bestimmung des Geschlechts an Vogeleiern | |
EP1889039B1 (de) | Verfahren und vorrichtung zur optischen charakterisierung von gewebe | |
DE69838560T2 (de) | Essigsäure als signalverbesserendes kontrastmittel in der fluoreszenzspektroscopie | |
DE69203153T2 (de) | Nadel mittels eines Photosensibilisators mit verbesserter Fluoreszenzbiopsie. | |
DE10133451B4 (de) | Vorrichtung zum Erkennen von Karies, Plaque, Konkrementen oder bakteriellem Befall an Zähnen | |
DE68925586T2 (de) | Verfahren für laserinduzierte fluoreszenz von gewebe | |
DE102006029809B3 (de) | Ortsaufgelöstes Messverfahren für die Detektion von Melanin in Fluorophorgemischen in einer Festkörperprobe | |
DE10202050A1 (de) | Optisches Bildgebungsverfahren und Vorrichtung zur optischen Bildgebung | |
WO2007079943A1 (de) | Faseroptisches fluoreszenzsensorsystem | |
EP2430427A1 (de) | Verfahren und vorrichtung zur erkennung von tumorbehaftetem lebendem zellgewebe | |
EP3685781A1 (de) | Vorrichtung zur gewebekoagulation | |
WO2011160892A1 (de) | Verfahren und vorrichtung zur erkennung von tumorbehaftetem gewebe im gastrointestinaltrakt mit hilfe einer endokapsel | |
EP3865052A1 (de) | Messsystem und messverfahren zur bestimmung von sonnenschutzfaktoren von sonnenschutzmitteln | |
EP2251675A1 (de) | Verfahren zur Erkennung von Tumorbehaftetem Zellgewebe | |
DE102010028105A1 (de) | Verfahren, Vorrichtung und Gerätesystem für die Therapie von Prostatakrebs | |
DE102018105067A1 (de) | Bildgebendes System zur nichtinvasiven optischen Untersuchung von Gewebe in der Tiefe | |
DE102014107342B4 (de) | Vorrichtung und Verfahren zur Erkennung von Krebstumoren und anderen Gewebeveränderungen | |
DE102020119026A1 (de) | Messsystem und Messverfahren | |
DE102014222997B3 (de) | Vorrichtung zur Untersuchung einer biologischen Probe auf Kontrastmittel | |
WO2005094670A1 (de) | Verfahren und gerät zur detektion eines in den körper eines lebewesens injizierten farbstoff-bolus | |
DE9112188U1 (de) | Laser-Diagnose- und Therapie-Gerät zur Tumorbehandlung | |
DE102013104959B4 (de) | Verfahren und Vorrichtung zur Abstandsüberwachung zwischen einer Sonde und einem fluoreszierenden Objekt | |
DE102007045988A1 (de) | Spektroskopieeinheit zur Durchführung einer magnetresonanzgeführten Lichtspektroskopie im Innern eines Untersuchungsobjektes sowie System zur magnetresonanzgeführten Lichtspektroskopie | |
DE102020108957B4 (de) | Vorrichtung, Verfahren und Computerprogramm zur Fluoreszenzmessung |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20111212 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR |
|
DAX | Request for extension of the european patent (deleted) | ||
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: SIEMENS AKTIENGESELLSCHAFT Owner name: FRAUNHOFER-GESELLSCHAFT ZUR FOERDERUNG DER ANGEWAN |
|
17Q | First examination report despatched |
Effective date: 20130906 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: FRAUNHOFER-GESELLSCHAFT ZUR FOERDERUNG DER ANGEWAN Owner name: SIEMENS HEALTHCARE GMBH |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN |
|
18W | Application withdrawn |
Effective date: 20170914 |